Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

DelMar Reveals Plan for China Trial of Lung Cancer Drug

publication date: Sep 9, 2015
DelMar Pharma, a Vancouver-Menlo Park, CA company, together with its China partner, Guangxi Wuzhou Pharma, announced plans to start a China Phase IV trial of VAL-083 in patients with refractory and relapsed non-small cell lung cancer. The drug is already approved for NSCLC in China, but most patients are prescribed newer tyrosine kinase inhibitors. Based on preclinical studies, DelMar believes VAL-083 is effective against TKI-resistant NSCLC, which the trial is designed to prove. More details....

Stock Symbol: (OTCQX: DMPI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here